Iran Darou Seeks to License a Leading Canadian Sports Supplement Brand

According to the report from Barkat Health & Pharmaceutical Group, Dr. Meysam Meftahi, during the Annual General Meeting of Iran Darou – one of the subsidiaries of the Barkat Health & Pharmaceutical Group – announced that for the fiscal year ending on December 21, 2024 (1403/09/30), Iran Darou produced 625 million units of products and recorded a sales revenue of 581 billion Iranian Rials. Furthermore, 65% of the company’s total sales were attributed to pharmaceuticals, while 35% came from supplements, with 44% of pharmaceuticals and 15% of supplements currently in the pipeline.

The CEO of Iran Darou further emphasized that 1403 was an exceptionally challenging year for the pharmaceutical industry, as the period for collecting receivables extended beyond one year. However, by the end of 1403, the issue of price adjustments was successfully addressed, and new pricing was implemented for the majority of products.

He also mentioned that the spray production line was completely overhauled and modernized, and for the first time, it was granted GMP (Good Manufacturing Practice) certification. Additionally, this year, the company is set to obtain production licenses for five new products.

Dr. Meftahi went on to state that in 1403, Iran Darou’s exports reached USD 625,000, compared to USD 157,000 in 1402. The export target for the current year stands at USD 800,000, with USD 505,000 already achieved in exports during March alone.

In conclusion, Dr. Meftahi highlighted that Iran Darou not only became the first in the country to produce artificial saliva spray, but the establishment of a renowned umbrella brand and the production of supplements under the license of a leading Canadian brand are key initiatives for the company in the current year.